Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1997-07-17
2001-04-17
Eyler, Yvonne (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023500, C435S320100, C435S252300, C435S325000
Reexamination Certificate
active
06218521
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to the isolation of genes associated with gastric cancer, methods of diagnosing gastric cancer using these, as well as other genes which are known, as well as therapeutic approaches to treating such conditions.
BACKGROUND AND PRIOR ART
It is fairly well established that many pathological conditions, such as infections, cancer, autoimmune disorders, etc., are characterized by the inappropriate expression of certain molecules. These molecules thus serve as “markers” for a particular pathological or abnormal condition. Apart from their use as diagnostic “targets”, i.e., materials to be identified to diagnose these abnormal conditions, the molecules serve as reagents which can be used to generate diagnostic and/or therapeutic agents. A by no means limiting example of this is the use of cancer markers to produce antibodies specific to a particular marker. Yet another non-limiting example is the use of a peptide which complexes with an MHC molecule, to generate cytolytic T cells against abnormal cells.
Preparation of such materials, of course, presupposes a source of the reagents used to generate these. Purification from cells is one laborious, far from sure method of doing so. Another preferred method is the isolation of nucleic acid molecules which encode a particular marker, followed by the use of the isolated encoding molecule to express the desired molecule.
To date, two strategies have been employed for the detection of such antigens, in e.g., human tumors. These will be referred to as the genetic approach and the biochemical approach. The genetic approach is exemplified by, e.g., dePlaen et al., Proc. Natl. Sci. USA 85: 2275 (1988), incorporated by reference. In this approach, several hundred pools of plasmids of a cDNA library obtained from a tumor are transfected into recipient cells, such as COS cells, or into antigen-negative variants of tumor cell lines. Transfectants are screened for the expression of tumor antigens via their ability to provoke reactions by anti-tumor cytolytic T cell clones. The biochemical approach, exemplified by, e.g., Mandelboim, et al., Nature 369: 69 (1994) incorporated by reference, is based on acidic elution of peptides which have bound to MHC-class I molecules of tumor cells, followed by reversed-phase high performance liquid chromography (HPLC). Antigenic peptides are identified after they bind to empty MHC-class I molecules of mutant cell lines, defective in antigen processing, and induce specific reactions with cytolytic T-lymphocytes (“CTLs”) These reactions include induction of CTL proliferation, TNF release, and lysis of target cells, measurable in an MTT assay, or a
51
Cr release assay.
These two approaches to the molecular definition of antigens have the following disadvantages: first, they are enormously cumbersome, time-consuming and expensive; second, they depend on the establishment of CTLs with predefined specificity; and third, their relevance in vivo for the course of the pathology of disease in question has not been proven, as the respective CTLs can be obtained not only from patients with the respective disease, but also from healthy individuals, depending on their T cell repertoire.
The problems inherent to the two known approaches for the identification and molecular definition of antigens is best demonstrated by the fact that both methods have, so far, succeeded in defining only very few new antigens in human tumors. See, e.g., van der Bruggen et al., Science 254: 1643-1647 (1991); Brichard et al., J. Exp. Med. 178: 489-495 (1993); Coulie, et al., J. Exp. Med. 180: 35-42 (1994); Kawakami, et al., Proc. Natl. Acad. Sci. USA 91: 3515-3519 (1994).
Further, the methodologies described rely on the availability of established, permanent cell lines of the cancer type under consideration. It is very difficult to establish cell lines from certain cancer types, as is shown by, e.g., Oettgen, et al., Immunol. Allerg. Clin. North. Am. 10: 607-637 (1990). It is also known that some epithelial cell type cancers are poorly susceptible to CTLs in vitro, precluding routine analysis. These problems have stimulated the art to develop additional methodologies for identifying cancer associated antigens.
One key methodology is described by Sahin, et al., Proc. Natl. Acad. Sci. USA 92: 11810-11913 (1995), incorporated by reference. Also, see U.S. Pat. Nos. 6,025,191, and 5,698,396. All three of these references are incorporated by reference. To summarize, the method involves the expression of cDNA libraries in a prokaryotic host. (The libraries are secured from a tumor sample). The expressed libraries are then immunoscreened with absorbed and diluted sera, in order to detect those antigens which elicit high titer humoral responses. This methodology is known as the SEREX method (“Serological identification of antigens by Recombinant Expression Cloning”). The methodology has been employed to confirm expression of previously identified tumor associated antigens, as well as to detect new ones. See the above referenced patent applications and Sahin, et al., supra, as well as Crew, et al., EMBO J 144: 2333-2340 (1995).
The SEREX methodology has now been applied to stomach cancer samples. Several nucleic acid molecules have been newly isolated and sequenced, and are now associated with stomach cancer. Further, a pattern of expression involving these, as well as previously isolated genes has been found to be associated with stomach cancer. These results are the subject of this application, which is elaborated upon in the disclosure which follows.
REFERENCES:
patent: 5698396 (1997-12-01), Pfreundschuh
dePlaen et al.,Proc. Natl. Sci. USA85:2275, 1988.
Mandelboim, et al.,Nature369:69 1994.
van der Bruggen et al.,Science254:1643-1647, 1991.
Brichard et al.,J. Exp. Med. 178:489-495, 1993.
Coulie et al.,J. Exp. Med. 180:35-42, 1994.
Kawakami et al.,Proc. Natl. Acad. Sci, USA91:3515-3519, 1994.
Oettgen et al.,Immunol. Allerg. Clin. North. Am, 10:607-637, 1990.
Sahin et al.,Proc. Natl. Acad. Sci. USA92:11810-11913, 1995.
Crew et al.,EMBO J144:2333-2340, 1995.
Chen et al.,Proc. Natl. Acad. Sci. USA94:1914 (1997).
Türeci et al.,Cancer Research56:4766-4772, 1996.
1994-1995 Promega Catalog, p. 167.*
Genebank Accession No: N25768 (Dec. 29, 1995).*
Genebank Accession No: N28891 (Jan. 4, 1996).*
Genebank Accession No: W74607 (Jun. 20, 1996).*
Genebank Accession No: AA 004205 (Jul. 23, 1996).*
Genebank Accession No: AA 007407 (Jul. 25, 1996).*
Genebank Accession No: T24694 (Oct. 9, 1996).*
Genebank Accession No: W45570 (Oct. 10, 1996).*
Genebank Accession No: W92012 (Feb. 2, 1997).*
Genebank Accession No: AA114952 (May. 11, 1997).*
Genebank Accession No: AA431793 (May 22, 1997).
Eyler Yvonne
Ludwig Institute for Cancer Research
Nichols Jennifer
Wolf Greenfield & Sacks P.C.
LandOfFree
Isolated nucleic acid molecules associated with gastric... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated nucleic acid molecules associated with gastric..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated nucleic acid molecules associated with gastric... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2484851